远程医疗公司Hims & Hers Health (HIMS.US)公布2024年第四季度业绩。数据显示，该公司Q4营收同比增长95%至4.81亿美元，好于市场预期的4.7亿美元;每股收益为11美分，也好于市场预期的10美分。

但当 HIMS 在 12 月 6 日达到其最后一个波动高点时（使用收盘价），该股的收盘价为 34.23 美元，仅比其 50 天移动平均线 23.29 美元高出 47%。同样，其 2024 年 6 月 18 日的波动高点比当时的 50 天移动平均线高出 ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

Hims & Hers reported a double beat in Q4, but faced an 18% stock drop after hours. Read why this drop is a good opportunity ...

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...

Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...

Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...

Shares of Hims & Hers Health fell, dragged down by expectations that the telehealth-consultation platform will have to stop selling its weight-loss treatments, which boosted results in the fourth ...

Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...